Karen Evans, DO
Family Medicine · Lawrence, KSNPI 1992758957
Payments from drug & device makers
Across 137 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$317
- Lilly USA, LLC$268
- Novo Nordisk$235
- Pfizer$221
- Regeneron Healthcare Solutions, Inc.$196
- Abbott$185
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,47599%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $317 |
| Lilly USA, LLC | 16 | $268 |
| Novo Nordisk | 15 | $235 |
| Pfizer | 17 | $221 |
| Regeneron Healthcare Solutions, Inc. | 9 | $196 |
| Abbott | 9 | $185 |
| Astellas Pharma US Inc | 6 | $145 |
| AstraZeneca | 9 | $130 |
| Dexcom, Inc. | 3 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $111 |
| Amgen | 7 | $110 |
| Noven Therapeutics, LLC | 5 | $95 |
| Axsome Therapeutics, Inc. | 1 | $77 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Medtronic | 1 | $35 |
| Boston Scientific | 1 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Nalu Medical, Inc. | 1 | $25 |
| Agile Therapeutics, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| GSK | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$2,490 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $117,265 |
| MounjaroTirzepatide | 61 | $73,760 |
| EliquisApixaban | 46 | $34,091 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $30,413 |
| JardianceEmpagliflozin | 29 | $22,110 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $21,554 |
| RybelsusSemaglutide | 17 | $21,077 |
| XareltoRivaroxaban | 16 | $18,982 |
| FarxigaDapagliflozin Propanediol | 15 | $13,173 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $10,143 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $10,037 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,146 |
| Testosterone | 21 | $6,358 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $4,608 |
| PremarinEstrogens, Conjugated | 16 | $3,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $235 | $138,342120 claims |
| Lilly USA, LLCMounjaro | $268 | $73,76061 claims |
| PfizerEliquis, Premarin | $221 | $37,99162 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $30 | $32,14740 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $130 | $22,31930 claims |
| AbbVieSynthroid | $317 | $1,23914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Lawrence
- Myra StrotherLawrence$562K
- David StricklandLawrence$53K
- Larisa KimuriLawrence$23K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.